---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-25-000037"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T02:00:52.019547+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue

## Summary
- Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).
- Revenue growth driven by volume from Mounjaro and Zepbound; non-incretin revenue grew 20%.
- 2025 guidance: revenue $58.0-61.0B, reported EPS $22.05-23.55, non-GAAP EPS $22.50-24.00.
- Pipeline: FDA approved Zepbound for OSA and Omvoh for Crohn's; Kisunla approved in China.
- Board authorized $15B share repurchase program and 15% dividend increase.

## SEC filing metadata
- accession: 0000059478-25-000037
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947825000037/0000059478-25-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947825000037/lly-20250206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-25-000037
- JSON: https://secwatch.observer/filing/0000059478-25-000037.json
- Plain text: https://secwatch.observer/filing/0000059478-25-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.